Metropolis Healthcare has launched a new Blood Based Test For Early Alzheimer’s Screening, marking a significant advancement in neurological diagnostics in India. The test is designed to detect biomarkers associated with Alzheimer’s disease at an early stage potentially even before noticeable symptoms appear.
The innovation focuses on identifying specific proteins in the blood that are linked to the development of Alzheimer’s, offering a less Invasive And More Accessible Alternative to traditional diagnostic methods such as brain imaging or spinal fluid analysis. This aligns with global research trends, where blood based biomarkers are increasingly seen as a breakthrough in early dementia detection.
Early detection is critical in Alzheimer’s care, as it allows for timely medical intervention, lifestyle adjustments, and better disease management. With India witnessing a growing burden of neurodegenerative disorders due to an aging population, such advancements are expected to play a crucial role in improving long term patient outcomes.
As one of India’s leading diagnostic chains with a wide network of labs and advanced testing capabilities, Metropolis aims to make this screening more widely available across the country. The launch also reflects a broader shift in healthcare toward Preventive And Predictive Diagnostics, where diseases are identified earlier to enable more effective treatment strategies.
Experts believe that blood based Alzheimer’s screening could significantly reduce diagnostic delays, improve clinical decision making, and support large scale screening programs in the future. While further validation and clinical adoption will continue to evolve, the test represents a major step toward making early Alzheimer’s detection more practical and scalable.
“Early detection through a simple blood test could change the course of Alzheimer’s care before symptoms even begin.”
By
HB Team
Related News
